Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F, Héron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhommé C, Macé-Lesec'h J, Crouet H. Joly F, et al. Among authors: lhomme c. Gynecol Oncol. 2000 Sep;78(3 Pt 1):361-8. doi: 10.1006/gyno.2000.5923. Gynecol Oncol. 2000. PMID: 10985895 Clinical Trial.
Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.
Guastalla JP, Lhomme C, Kerbrat P, Mayer F, Namer M, Goupil P, Charrot P, Heron JF, Chazard M, Richard I, et al. Guastalla JP, et al. Among authors: lhomme c. Ann Oncol. 1994 Feb;5(2):127-32. doi: 10.1093/oxfordjournals.annonc.a058763. Ann Oncol. 1994. PMID: 8186155 Free article. Clinical Trial.
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.
Lhommé C, Vennin P, Callet N, Lesimple T, Achard JL, Chauvergne J, Luporsi E, Chinet-Charrot P, Coudert B, Couette JE, Guastalla JP, Lebrun D, Ispas S, Blumberg J. Lhommé C, et al. Gynecol Oncol. 1999 Nov;75(2):187-93. doi: 10.1006/gyno.1999.5538. Gynecol Oncol. 1999. PMID: 10525370 Clinical Trial.
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand JP, Chevallier B, Kerbrat P, de Forni M, Lhommé C, Roche H, et al. Chauvergne J, et al. Among authors: lhomme c. Eur J Cancer. 1993;29A(3):350-4. doi: 10.1016/0959-8049(93)90384-r. Eur J Cancer. 1993. PMID: 8398333 Clinical Trial.
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Lhommé C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, Van Glabbeke M, Matthieu-Boué A, Mignard D, Chevallier B. Lhommé C, et al. J Clin Oncol. 1999 Oct;17(10):3136-42. doi: 10.1200/JCO.1999.17.10.3136. J Clin Oncol. 1999. PMID: 10506610 Clinical Trial.
274 results